Enlicitide chloride

iStock, jittawit.21 Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing. Scribe Therapeutics is testing whether investors will embrace an earlier-stage bet in a market that favors derisked IPO stories. But Scribe’s outlier status goes far beyond the fact that the biotech filed to go public around the same time it was heading into the clinic. Less than a month since debuting and raising an upsized $150 million, Scribe—the only public company with an epigenetic silencer in the clinic—has seen its stock rise 43% from its first-day price of $21.50, resting at $31.05 by close on Wednesday. In comparison, biotech’s industry stock index, known as the XBI, has risen 12% over the last month. Beyond bucking the trend of late-stage biotechs with derisked assets debuting, the CRISPR-focused company is “a story that very quickly will be validated one way or the other, meaning they’re going to have a data update early next year,” Jack Bannister, senior managing director of equity capital markets at Leerink Partners, told BioSpace . Leerink served as one of the book-running managers for Scribe’s IPO. The biotech has designed a single dose of its main asset STX-1150 to lower LDL cholesterol (LDL-C), often known as “bad” cholesterol. The asset leverages epigenetic silencing, as opposed to gene editing, in hopes of significantly lowering the risk of atherosclerotic cardiovascular disease (ASCVD) without permanently changing the DNA sequence. STX-1150 targets PCSK9 and is currently entering Phase 1 trials in Australia, with interim results in patients with high LDL-C set to read out in the first half of next year. Beyond a clean safety profile, Leerink analysts hope STX-1150 can reduce LDL-C by 50% or more, which would translate to significantly improved adherence-adjusted efficacy compared to approved drugs such as Amgen’s Repatha, Novartis’ and Alnylam’s Leqvio or Merck’s newly approved Lipfendra , according to an Aug. 18 note. “We believe a positive readout [for Scribe] would drive a meaningful value inflection,” Leerink wrote. The analysts pointed to Eli Lilly’s $1 billion upfront acquisition of gene editor Verve Therapeutics last year, which came on the heels of Phase 1b safety and LDL-C lowering results among only 14 patients. “It’s the kind of dataset where investors should know quickly whether the drug’s working or not, and so it could be a material value inflection point right out of the gate,” Bannister said about Scribe, comparing the situation to the many biotechs that start with healthy volunteers or are just looking for safety signals early on. “That’s not Scribe. At Scribe, you should have a pretty good sense early and quickly whether it’s worth something or not.” Leerink believes STX-1150, which is delivered via lipid nanoparticle, could offer similar efficacy to current PCSK9-targeting injections or daily pills, while also improving convenience. The candidate is also designed to be safer than gene editors since no permanent genetic changes are made. Scribe also differs from other newly public biotechs in fundraise size. The valuation of the IPO is considerably lower, especially compared to record-breakers Kailera Therapeutics’ $625 million debut and Parabilis Medicines’ subsequent $670 million IPO . That’s by design, Bannister explained. “It was important for us to find a price that was attractive to not just existing investors but new investors as well,” he said, adding that they wanted to “price the deal to trade well.” The strategy seems to be paying off. While Scribe hasn’t been on the market as long as either Kailera or Parabilis, the biotech’s stock has risen more than the other two, with Kailera at a 31.4% loss from its first-day price and Parabilis up 24.5% as of Aug. 18, according to BioSpace ’s performance tracker . “Valuation matters. Companies who have leaned in too hard on value and tried to push at too high of a price haven’t traded as well this year,” Bannister said. “Those who have been much more conservative on price have traded well. It’s not a coincidence, right?” IPO Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom After debuting on the public markets with $256.3 million and raking in an additional $472 million , Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels. July 6, 2026 · 5 min read · Gabrielle Masson Read more Leerink believes Scribe will outperform market expectations, forecasting a $37 price target, according to the analyst note. The California-based biotech was co-created by four CRISPR pioneers, including CEO Benjamin Oakes and Nobel Prize winner Jennifer Doudna. Beyond main asset STX-1150, Scribe has also built a gene editing platform called X-Editor that underpins two potential pipeline candidates: STX-1200 for Lp(a) and STX-1400 for severe hypertriglyceridemia—the other two lipid drivers of ASCVD. This platform has already attracted deals from two major pharmas, Sanofi and Eli Lilly —something Leerink dubs “impressive external validation.” Both pharma companies invested in Scribe’s IPO as well. The biotech expects its cash runway to carry it into the first half of 2029.

Amgen lifted its full-year guidance on Tuesday after reporting an uptick in second-quarter sales that beat analyst expectations. Carried by 26% growth across its six key growth drivers — which represented nearly 70% of its product sales for the three-month period — Amgen said its total revenues climbed 10% year-over-year to $10.1 billion, topping estimates of $9.4 billion. The company's second-quarter adjusted earnings of $6.29 per share also blew past expectations of $5.62, an increase of 4% from the year-ago period.Its top-performing product was cholesterol-lowering drug Repatha. The injectable PCSK9 inhibitor raked in $953 million in sales for the quarter, a jump of 37% compared to the year-ago period to come out ahead of the Street's sales prediction of $916 million.Primarily used in the secondary cardiovascular prevention setting to lower risk in individuals with a history of heart attack, stroke or other cardiac events, Repatha gained an expanded drug label last year to cover primary prevention (see – ViewPoints: Repatha poised for major step-up in primary prevention use).But despite the rosy financial print, Repatha is now facing down competition in the form of Lipfendra, an oral PCSK9 inhibitor from Merck & Co. that will cost roughly half as much as the incumbent injectable. Approved by the FDA last month to lower LDL cholesterol, doctors are already eager to start prescribing Lipfendra. A recent FirstWord poll showed 38% of physicians would definitely prescribe it, with 43% reporting they probably would. As for switching from injectables, 21% expressed certainty that they would, while 43% said it was probable (see – Physician Views Results: Prescribers are ready to embrace Merck & Co.'s oral PCSK9 and Spotlight On: Updated Physician Views poll data shows particularly strong support for Merck & Co.'s Lipfendra from US cardiologists).However, Amgen management didn't seem phased by Lipfendra's potential to steal market share away from Repatha, based on comments made during the company's call with investors on Tuesday. "Obviously the two labels really just don't compare," said Murdo Gordon, Amgen's EVP, global markets and policy. He noted that Repatha has a "broad label that includes primary and secondary prevention…[and] can be used as monotherapy or in combination with statins," with 10 years of real-word evidence backing the injectable's use. "The data behind Repatha are unrivalled. It is the category leader," he added. He also emphasised that "oral versus injectable is too simplistic a comparison," given there are many patients who are still not at their LDL cholesterol goal. "You really have to look at, 'Why do you take an LDL cholesterol medicine in the first place, and is it to prevent a first or second heart attack?' And we've demonstrated that with very clear evidence for Repatha."Other growth driversIn addition to Repatha, Amgen highlighted osteoporosis treatment Evenity and asthma drug Tezspire as key growth drivers. Second-quarter sales of the former rose 38% year-over-year to $714 million, beating estimates of $645 million, while the latter brought in $486 million in revenues, representing a 42% jump compared with the same period in 2025. Given the increase in sales, Amgen raised its full-year outlook for 2026. It now expects adjusted earnings of $22.30 to $23.50 per share on revenues in the range of $38.2 billion to $39.4 billion, up from an earlier projection that adjusted earnings would come in between $21.70 to $23.10 per share on revenues of $37.1 billion to $38.5 ​billion. Based on the midpoint of its updated guidance, Amgen is now estimating $1 billion more in revenues for the year. Obesity candidate cutWhile Amgen didn't share any new data for its obesity hopeful MariTide, it did note that the GLP-1 agonist/GIP antagonist is now its only clinical asset in development for weight loss — as it has axed its only other programme in the category.The drugmaker said it is discontinuing development of AMG 513, which is in Phase I study involving adults with obesity. The early-stage candidate's mechanism was never disclosed."The bar is high at Amgen for obesity medicines," said Jay Bradner, Amgen's EVP of R&D. "Our next generation of differentiated preclinical programmes continues to progress, featuring both incretin and non-incretin mechanisms of action."